Recital 5, Regulation (EU) 2020/16

In forcesince 10 Jan 2020

The Applicant also made a request to the Commission for the protection of proprietary data for a number of studies submitted in support of the application namely, an in vitro study evaluating the metabolism of nicotinamide riboside in blood (Study No 160312) [Keystone Bioanalytical Inc., The Metabolism of Nicotinamide Riboside in Human Blood (Study No 160312), 10 January 2018, unpublished.]; an oral 7-day dose range finding toxicity study in juvenile dogs (StudyNo 17-921) [Experimur, Oral 7-Day Dose Range Finding Toxicity Study in Juvenile Dogs (Study No 17-921), 27 November 2017, unpublished.]; a hERG screening assay (Study No 20151223) [IPS Therapeutique, Inc., Evaluation of the effects of Nicotinamide Riboside Chloride on the human potassium channel using human embryonic kidney (HEK) 293 cells transfected with a human ether-a-go-go-related gene (hERG), 25 March 2016, unpublished.]; a 28-day repeat-dose oral toxicity study in juvenile dogs (Study No 17-940) [Experimur, Oral 28-Day Toxicity Study in Juvenile Dogs (Study No 17-940), 20 February 2018, unpublished.]; a 90-day repeated-dose oral toxicity study in Sprague–Dawley rats (Study No S14022) [Syngene International Limited, Comparative 90-Day Oral Toxicity Study in Sprague Dawley Rats (Study No S14022), 12 May 2015, unpublished.]; a reproductive toxicity study (Study No G10959) [Advinus Therapeutics Limited, Nicotinamide riboside chloride: one generation reproduction toxicity study through diet in Sprague-Dawley rats (Study No G10959), 21 November 2016, unpublished.]; and a developmental toxicity study in rats (Study No G10957) [Advinus Therapeutics Limited, Nicotinamide riboside chloride: embryo-fetal developmental toxicity study in Sprague-Dawley rats by oral route (Study No G10957), 30 September 2016.].